Thomas Bo Jensen1, Dorthe Bartels2, Eva Aggerholm Sædder3, Birgitte Klindt Poulsen4, Stig Ejdrup Andersen5, Mette Marie H Christensen6, Lars Nielsen7, Hanne Rolighed Christensen8. 1. Department of Clinical Pharmacology, Copenhagen University Hospital Bispebjerg, Entrance 20C, Bispebjerg Bakke 23, DK-2400, Copenhagen, NV, Denmark. Thomas.Bo.Jensen@regionh.dk. 2. Amgros - The Regions' Pharmaceutical Organisation, Copenhagen, Denmark. 3. Department of Clinical Pharmacology, Aarhus University Hospital, Aarhus, Denmark. 4. Department of Clinical Pharmacology, Aalborg University Hospital, Aalborg, Denmark. 5. Clinical Pharmacology Unit, Zealand University Hospital, Roskilde, Denmark. 6. Department of Clinical Biochemistry and Pharmacology, Odense University Hospital, Odense, Denmark. 7. The Hospital Pharmacy of the Capital Region of Denmark, Herlev, Denmark. 8. Department of Clinical Pharmacology, Copenhagen University Hospital Bispebjerg, Entrance 20C, Bispebjerg Bakke 23, DK-2400, Copenhagen, NV, Denmark.
Abstract
PURPOSE: A rapidly increasing use of biological drugs has led to substantial costs. Shift to biosimilars enables considerable reduction of these costs without jeopardizing the treatment of patients, but most countries have extensive possibilities of untapped cost-savings. The aim of this study was to describe the Danish quick and near-complete implementation of the two first TNF inhibitor biosimilars (infliximab and etanercept). METHODS: We shed light on the considerations and experiences made during the implementation, and present key figures from the implementation. RESULTS: The infliximab biosimilar constituted 90.6% of the total amount of infliximab four months following patent expiration of the biooriginator. Similar results were seen for etanercept biosimilar. Substantial cost reductions were experienced in the way that e.g. the infliximab-shift reduced cost by two thirds. CONCLUSION: We believe that a thorough preparation and an organizational setting supporting the implementation is crucial for the successful implementation. This same implementation model will be used for future biosimilars.
PURPOSE: A rapidly increasing use of biological drugs has led to substantial costs. Shift to biosimilars enables considerable reduction of these costs without jeopardizing the treatment of patients, but most countries have extensive possibilities of untapped cost-savings. The aim of this study was to describe the Danish quick and near-complete implementation of the two first TNF inhibitor biosimilars (infliximab and etanercept). METHODS: We shed light on the considerations and experiences made during the implementation, and present key figures from the implementation. RESULTS: The infliximab biosimilar constituted 90.6% of the total amount of infliximab four months following patent expiration of the biooriginator. Similar results were seen for etanercept biosimilar. Substantial cost reductions were experienced in the way that e.g. the infliximab-shift reduced cost by two thirds. CONCLUSION: We believe that a thorough preparation and an organizational setting supporting the implementation is crucial for the successful implementation. This same implementation model will be used for future biosimilars.
Authors: Pekka Kurki; Leon van Aerts; Elena Wolff-Holz; Thijs Giezen; Venke Skibeli; Martina Weise Journal: BioDrugs Date: 2017-04 Impact factor: 5.807
Authors: B Glintborg; T Kringelbach; N Bolstad; D J Warren; G Eng; I J Sørensen; A G Loft; O Hendricks; Imj Hansen; A Linauskas; H Nordin; S Kristensen; H Lindegaard; D V Jensen; G L Goll; E Høgdall; J Gehin; C Enevold; C H Nielsen; N S Krogh; J S Johansen; M L Hetland Journal: Scand J Rheumatol Date: 2018-01-09 Impact factor: 3.641
Authors: Soo Kyung Cho; Sun Young Jung; Hyoungyoung Kim; Yeo Jin Song; Kyungeun Lee; Yoon Kyoung Sung Journal: J Korean Med Sci Date: 2021-05-24 Impact factor: 2.153
Authors: Louise C Druedahl; Sofia Kälvemark Sporrong; Timo Minssen; Hans Hoogland; Marie Louise De Bruin; Marco van de Weert; Anna Birna Almarsdóttir Journal: PLoS One Date: 2022-01-11 Impact factor: 3.240
Authors: Tara Gomes; Daniel McCormack; Sophie A Kitchen; J Michael Paterson; Muhammad M Mamdani; Laurie Proulx; Lorraine Bayliss; Mina Tadrous Journal: CMAJ Open Date: 2021-11-23
Authors: Josef S Smolen; Roberto Caporali; Thomas Doerner; Bruno Fautrel; Fabrizio Benedetti; Burkhard Pieper; Minjun Jang Journal: RMD Open Date: 2021-06